CDK7-IN-2
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII) . CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1) [1].
Product Specifications
CAS Number
[2326428-19-5]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk7-in-2.html
Purity
98.93
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1CCC(NC2=CC(C)=NC3=C(C(C)C)C=NN23)CC1)O[C@@H]4CN(C(/C=C/CN(C)C)=O)CC4
Molecular Formula
C26H39N7O3
Molecular Weight
497.63
Precautions
H315, H319, H335
References & Citations
[1]David Andrew Coates, et al. Compounds useful for inhibiting cdk7. Patent WO2019099298A1.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Human Monoclonal B7-H3/CD276 Antibody (omburtamab) [Janelia Fluor 585]
